HAART + Immunotherapy

Juan A. Arnaiz · FDA-approved active Small molecule

HAART + Immunotherapy is a Combination antiretroviral + immunotherapy Small molecule drug developed by Juan A. Arnaiz. It is currently FDA-approved for HIV infection with immunotherapy enhancement, HIV-associated malignancies. Also known as: Cyclosporine A, GM-CSF, Peg-IFN, Interleukin-2.

HAART (highly active antiretroviral therapy) suppresses HIV replication while immunotherapy enhances the immune system's ability to recognize and eliminate HIV-infected cells and tumors.

HAART (highly active antiretroviral therapy) suppresses HIV replication while immunotherapy enhances the immune system's ability to recognize and eliminate HIV-infected cells and tumors. Used for HIV infection with immunotherapy enhancement, HIV-associated malignancies.

At a glance

Generic name	HAART + Immunotherapy
Also known as	Cyclosporine A, GM-CSF, Peg-IFN, Interleukin-2
Sponsor	Juan A. Arnaiz
Drug class	Combination antiretroviral + immunotherapy
Modality	Small molecule
Therapeutic area	Immunology, Infectious Disease, Oncology
Phase	FDA-approved

Mechanism of action

HAART uses a combination of antiretroviral drugs to reduce viral load and restore CD4+ T cell counts in HIV patients. Immunotherapy agents (such as checkpoint inhibitors or therapeutic vaccines) work synergistically to boost anti-HIV and anti-tumor immune responses, potentially improving viral control and addressing HIV-associated malignancies or comorbidities.

Approved indications

• HIV infection with immunotherapy enhancement
• HIV-associated malignancies

Common side effects

• Immune activation syndrome
• Gastrointestinal disturbances
• Hepatotoxicity
• Lipodystrophy
• Immune-related adverse events

Key clinical trials

• Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART (PHASE1, PHASE2)
• Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects (PHASE1)
• Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (PHASE1)
• Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV (PHASE2)
• A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART (PHASE1)
• Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD). (PHASE4)
• Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load (PHASE2)
• Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HAART + Immunotherapy CI brief — competitive landscape report
• HAART + Immunotherapy updates RSS · CI watch RSS
• Juan A. Arnaiz portfolio CI

Frequently asked questions about HAART + Immunotherapy

What is HAART + Immunotherapy?

HAART + Immunotherapy is a Combination antiretroviral + immunotherapy drug developed by Juan A. Arnaiz, indicated for HIV infection with immunotherapy enhancement, HIV-associated malignancies.

How does HAART + Immunotherapy work?

HAART (highly active antiretroviral therapy) suppresses HIV replication while immunotherapy enhances the immune system's ability to recognize and eliminate HIV-infected cells and tumors.

What is HAART + Immunotherapy used for?

HAART + Immunotherapy is indicated for HIV infection with immunotherapy enhancement, HIV-associated malignancies.

Who makes HAART + Immunotherapy?

HAART + Immunotherapy is developed and marketed by Juan A. Arnaiz (see full Juan A. Arnaiz pipeline at /company/juan-a-arnaiz).

Is HAART + Immunotherapy also known as anything else?

HAART + Immunotherapy is also known as Cyclosporine A, GM-CSF, Peg-IFN, Interleukin-2.

What drug class is HAART + Immunotherapy in?

HAART + Immunotherapy belongs to the Combination antiretroviral + immunotherapy class. See all Combination antiretroviral + immunotherapy drugs at /class/combination-antiretroviral-immunotherapy.

What development phase is HAART + Immunotherapy in?

HAART + Immunotherapy is FDA-approved (marketed).

What are the side effects of HAART + Immunotherapy?

Common side effects of HAART + Immunotherapy include Immune activation syndrome, Gastrointestinal disturbances, Hepatotoxicity, Lipodystrophy, Immune-related adverse events.

Related

• Drug class: All Combination antiretroviral + immunotherapy drugs
• Manufacturer: Juan A. Arnaiz — full pipeline
• Therapeutic area: All drugs in Immunology, Infectious Disease, Oncology
• Indication: Drugs for HIV infection with immunotherapy enhancement
• Indication: Drugs for HIV-associated malignancies
• Also known as: Cyclosporine A, GM-CSF, Peg-IFN, Interleukin-2